title: Hypotonic water as adjuvant therapy for incompletely resected canine mast cell tumors: a randomized, double-blind, placebo-controlled study.
abstract: OBJECTIVE
  To evaluate efficacy of hypotonic water as adjuvant therapy after marginal resection of canine mast cell tumors (MCT).
  
  
  METHODS
  Double-blinded, placebo-controlled, prospective, randomized study.
  
  
  METHODS
  Dogs (n=30) with spontaneous, cutaneous, solitary MCT.
  
  
  METHODS
  The wound bed of MCT, resected with margins <0.5 cm, was injected with either hypotonic or isotonic water according to a standardized protocol. Follow-up was obtained by clinical examination at 1, 2, 3, 6, and 12 months and annual telephone contact with the owner.
  
  
  RESULTS
  Eighteen dogs were treated with isotonic lactated Ringer's solution and 12 dogs with hypotonic distilled water. All MCT were stage 0 tumors and most grade II. Six tumors (4 isotonic, 2 hypotonic) recurred locally, 3 of these dogs died from disease-related reasons within 4 months. The surviving 3 dogs were alive with a median survival time (ST) of 1092 days. The calculated 2-year recurrence-free rate was 92.7%; the 2-year disease-free rate 79.1%; and the 2-year survival rate 89.5%. No significant differences in local recurrence and ST were observed between treatment groups. Histologic grading was the only significant prognosticator for ST and recurrence-free periods.
  
  
  CONCLUSIONS
  No significant differences in local recurrence and ST were observed between adjunctive hypotonic water and placebo treatment after marginal resection of solitary MCT.
  
  
  CONCLUSIONS
  Hypotonic water does not decrease the rate of local recurrence in dogs with solitary MCT after marginal surgical excision.
authors.affiliation: Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, The Netherlands.
authors.forename: Bouvien A W
authors.initials: BA
authors.lastname: Brocks
authors.forename: Isabelle J S
authors.initials: IJ
authors.lastname: Neyens
authors.forename: Erik
authors.initials: E
authors.lastname: Teske
authors.forename: Jolle
authors.initials: J
authors.lastname: Kirpensteijn
mesh_terms: D000818:Animals; D017024:Chemotherapy, Adjuvant / Q000662:veterinary; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004283:Dog Diseases / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D004285:Dogs; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D007038:Hypotonic Solutions / Q000627:therapeutic use*; D008297:Male; D012515:Mast-Cell Sarcoma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000662:veterinary*; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000662:veterinary; D011446:Prospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000662:veterinary*
chemical_list: D007038:Hypotonic Solutions